Drug intelligence / Profile preview

COMPOUND 43

Development stage: Preclinical
Modality: Small Molecules

Overview

COMPOUND 43 is a novel small molecule identified through docking-based virtual screening as a selective antagonist of the adenosine A2A receptor (AR). It exhibits substantial activity against the A2A AR with a Ki of 0.42 μM and demonstrates good selectivity over the A1 adenosine receptor. In functional assays, COMPOUND 43 showed antagonistic activity with a cAMP IC50 of 1.67 μM. Preclinical studies in the haloperidol-induced catalepsy (HIC) rat model, a model for Parkinson's disease, indicated good efficacy at doses up to 30 mg/kg, suggesting its potential as a therapeutic agent for Parkinson's disease.

Beyond the preview

Go deeper on COMPOUND 43.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COMPOUND 43.